Practice pattern for postoperative management of endometrial cancer in Japan

A survey of the Japanese Gynecologic Oncology Group

Yoh Watanabe, Ryo Kitagawa, Daisuke Aoki, Satoshi Takeuchi, Satoru Sagae, Noriaki Sakuragi, Nobuo Yaegashi

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objective: To determine the current status of postoperative management of endometrial cancer in Japan by surveying members of the Japanese Gynecologic Oncology Group (JGOG). Method: We conducted an original mail survey regarding the status of postoperative treatment including indication criteria, treatment procedures, and chemotherapeutic regimen among all 226 active member institutions of the JGOG. Results: A total of 199 institutions (88.1%) responded to the survey. A total of 4063 patients with endometrial cancer were treated at the member institutions of the JGOG over a year. As adjuvant therapy, chemotherapy (79.9%) was significantly (p < 0.01) preferred over radiotherapy (13.0%) or hormonal therapy (7.1%). Furthermore, more than 50% of respondent institutions performed adjuvant therapy when patients exhibited International Federation of Gynecology and Obstetrics (FIGO) stage IB/G3/positive lymph-vascular space invasion (LVSI)/endometrioid adenocarcinoma or FIGO IB/G3/non-endometrioid histology, and more than 90% institutions administered adjuvant therapy when patients exhibited FIGO IC/G3/positive LVSI/endometrioid adenocarcinoma or FIGO stage IC/G3/regardless of LVSI/non-endometrioid histology. A combination of paclitaxel and carboplatin was the most preferred first-line regimen for adjuvant chemotherapy followed by combination regimens consisting of anthracycline and platinum. Conclusion: The present survey provides relevant information regarding the current status of adjuvant therapy in Japanese patients with endometrial cancer.

Original languageEnglish
Pages (from-to)456-459
Number of pages4
JournalGynecologic Oncology
Volume115
Issue number3
DOIs
Publication statusPublished - 2009 Dec

Fingerprint

Endometrial Neoplasms
Japan
Gynecology
Obstetrics
Lymph
Endometrioid Carcinoma
Blood Vessels
Adjuvant Chemotherapy
Therapeutics
Histology
Anthracyclines
Carboplatin
Postal Service
Paclitaxel
Surveys and Questionnaires
Platinum
Radiotherapy

Keywords

  • Adjuvant therapy
  • Endometrial cancer
  • Japanese Gynecologic Oncology Group
  • Survey

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Practice pattern for postoperative management of endometrial cancer in Japan : A survey of the Japanese Gynecologic Oncology Group. / Watanabe, Yoh; Kitagawa, Ryo; Aoki, Daisuke; Takeuchi, Satoshi; Sagae, Satoru; Sakuragi, Noriaki; Yaegashi, Nobuo.

In: Gynecologic Oncology, Vol. 115, No. 3, 12.2009, p. 456-459.

Research output: Contribution to journalArticle

Watanabe, Yoh ; Kitagawa, Ryo ; Aoki, Daisuke ; Takeuchi, Satoshi ; Sagae, Satoru ; Sakuragi, Noriaki ; Yaegashi, Nobuo. / Practice pattern for postoperative management of endometrial cancer in Japan : A survey of the Japanese Gynecologic Oncology Group. In: Gynecologic Oncology. 2009 ; Vol. 115, No. 3. pp. 456-459.
@article{d25ecd98cb7a484d8eb08d167e2482a0,
title = "Practice pattern for postoperative management of endometrial cancer in Japan: A survey of the Japanese Gynecologic Oncology Group",
abstract = "Objective: To determine the current status of postoperative management of endometrial cancer in Japan by surveying members of the Japanese Gynecologic Oncology Group (JGOG). Method: We conducted an original mail survey regarding the status of postoperative treatment including indication criteria, treatment procedures, and chemotherapeutic regimen among all 226 active member institutions of the JGOG. Results: A total of 199 institutions (88.1{\%}) responded to the survey. A total of 4063 patients with endometrial cancer were treated at the member institutions of the JGOG over a year. As adjuvant therapy, chemotherapy (79.9{\%}) was significantly (p < 0.01) preferred over radiotherapy (13.0{\%}) or hormonal therapy (7.1{\%}). Furthermore, more than 50{\%} of respondent institutions performed adjuvant therapy when patients exhibited International Federation of Gynecology and Obstetrics (FIGO) stage IB/G3/positive lymph-vascular space invasion (LVSI)/endometrioid adenocarcinoma or FIGO IB/G3/non-endometrioid histology, and more than 90{\%} institutions administered adjuvant therapy when patients exhibited FIGO IC/G3/positive LVSI/endometrioid adenocarcinoma or FIGO stage IC/G3/regardless of LVSI/non-endometrioid histology. A combination of paclitaxel and carboplatin was the most preferred first-line regimen for adjuvant chemotherapy followed by combination regimens consisting of anthracycline and platinum. Conclusion: The present survey provides relevant information regarding the current status of adjuvant therapy in Japanese patients with endometrial cancer.",
keywords = "Adjuvant therapy, Endometrial cancer, Japanese Gynecologic Oncology Group, Survey",
author = "Yoh Watanabe and Ryo Kitagawa and Daisuke Aoki and Satoshi Takeuchi and Satoru Sagae and Noriaki Sakuragi and Nobuo Yaegashi",
year = "2009",
month = "12",
doi = "10.1016/j.ygyno.2009.08.016",
language = "English",
volume = "115",
pages = "456--459",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Practice pattern for postoperative management of endometrial cancer in Japan

T2 - A survey of the Japanese Gynecologic Oncology Group

AU - Watanabe, Yoh

AU - Kitagawa, Ryo

AU - Aoki, Daisuke

AU - Takeuchi, Satoshi

AU - Sagae, Satoru

AU - Sakuragi, Noriaki

AU - Yaegashi, Nobuo

PY - 2009/12

Y1 - 2009/12

N2 - Objective: To determine the current status of postoperative management of endometrial cancer in Japan by surveying members of the Japanese Gynecologic Oncology Group (JGOG). Method: We conducted an original mail survey regarding the status of postoperative treatment including indication criteria, treatment procedures, and chemotherapeutic regimen among all 226 active member institutions of the JGOG. Results: A total of 199 institutions (88.1%) responded to the survey. A total of 4063 patients with endometrial cancer were treated at the member institutions of the JGOG over a year. As adjuvant therapy, chemotherapy (79.9%) was significantly (p < 0.01) preferred over radiotherapy (13.0%) or hormonal therapy (7.1%). Furthermore, more than 50% of respondent institutions performed adjuvant therapy when patients exhibited International Federation of Gynecology and Obstetrics (FIGO) stage IB/G3/positive lymph-vascular space invasion (LVSI)/endometrioid adenocarcinoma or FIGO IB/G3/non-endometrioid histology, and more than 90% institutions administered adjuvant therapy when patients exhibited FIGO IC/G3/positive LVSI/endometrioid adenocarcinoma or FIGO stage IC/G3/regardless of LVSI/non-endometrioid histology. A combination of paclitaxel and carboplatin was the most preferred first-line regimen for adjuvant chemotherapy followed by combination regimens consisting of anthracycline and platinum. Conclusion: The present survey provides relevant information regarding the current status of adjuvant therapy in Japanese patients with endometrial cancer.

AB - Objective: To determine the current status of postoperative management of endometrial cancer in Japan by surveying members of the Japanese Gynecologic Oncology Group (JGOG). Method: We conducted an original mail survey regarding the status of postoperative treatment including indication criteria, treatment procedures, and chemotherapeutic regimen among all 226 active member institutions of the JGOG. Results: A total of 199 institutions (88.1%) responded to the survey. A total of 4063 patients with endometrial cancer were treated at the member institutions of the JGOG over a year. As adjuvant therapy, chemotherapy (79.9%) was significantly (p < 0.01) preferred over radiotherapy (13.0%) or hormonal therapy (7.1%). Furthermore, more than 50% of respondent institutions performed adjuvant therapy when patients exhibited International Federation of Gynecology and Obstetrics (FIGO) stage IB/G3/positive lymph-vascular space invasion (LVSI)/endometrioid adenocarcinoma or FIGO IB/G3/non-endometrioid histology, and more than 90% institutions administered adjuvant therapy when patients exhibited FIGO IC/G3/positive LVSI/endometrioid adenocarcinoma or FIGO stage IC/G3/regardless of LVSI/non-endometrioid histology. A combination of paclitaxel and carboplatin was the most preferred first-line regimen for adjuvant chemotherapy followed by combination regimens consisting of anthracycline and platinum. Conclusion: The present survey provides relevant information regarding the current status of adjuvant therapy in Japanese patients with endometrial cancer.

KW - Adjuvant therapy

KW - Endometrial cancer

KW - Japanese Gynecologic Oncology Group

KW - Survey

UR - http://www.scopus.com/inward/record.url?scp=70350569304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350569304&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2009.08.016

DO - 10.1016/j.ygyno.2009.08.016

M3 - Article

VL - 115

SP - 456

EP - 459

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -